The Goldman Sachs Group Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD – Get Free Report) had its price objective cut by research analysts at The Goldman Sachs Group from $399.00 to $375.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s price target would indicate a potential upside of […]

Leave a Reply

Your email address will not be published.

Previous post Dear Abby: Classless neighbors need to grow up
Next post Northcoast Research Reiterates Neutral Rating for Tetra Tech (NASDAQ:TTEK)